ArticleInflammatory bowel diseases2026
Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn's perianal fistula.
Article in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of Crohn's perianal fistula remains challenging owing to its recurrent nature and resistance to complete healing. This study aimed to assess the postoperative outcomes, including fistula closure rates, following Crohn's perianal fistula surgery, with and without polydeoxyribonucleotide administration.
methodsA retrospective review was conducted on patients who underwent fistula closure operations for Crohn's perianal fistula at a single tertiary center in Seoul, Korea, between January 2018 and June 2024. Patients were divided into two groups based on the use of local polydeoxyribonucleotide (PDRN) injections during fistula closure operations, and clinical variables and postoperative outcomes were compared between the groups.
resultsAmong the 47 patients, 21 (44.7%) were assigned to the PDRN group and 26 (55.3%) were assigned to non-PDRN group. Baseline characteristics between the two groups showed no significant difference. During the mean follow-up of 30.4 months, patients in the PDRN group demonstrated a significantly higher complete fistula closure rate (70.0% vs 26.9% at 6 months, and 83.3% vs 46.2% at 12 months; P = .005), and a shorter time from surgery to complete closure (3.3 ± 2.6 months vs 5.9 ± 3.8 months; P = .044), compared with the non-PDRN group. Multivariate analysis revealed PDRN as an independent factor significantly associated with Crohn's perianal fistula closure (HR 2.336; 95% CI, 1.092-4.997, P = .029).
conclusionsPDRN is a potential therapeutic agent that presents a viable option for Crohn's perianal fistula surgery, improving complete fistula closure rate through a safe, cost-effective, and relatively simple procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.